Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation

: Dichloroacetate (DCA), a small molecule mitochondria-targeting agent, can penetrate the blood–brain barrier, showing potential therapeutic effects on brain tumors. Considering the effects of DCA on tumor cellular metabolism, penetrating across the blood–brain barrier, as well as having potential antitumor activity on brain tumors, the purpose of this study is to investigate the antitumor activity of DCA on C6 glioma cells in vitro and in vivo. DCA inhibited C6 glioma cell proliferation, induced C6 cell apoptosis, and arrested C6 cells in S phase. DCA can inhibit the expression of heat shock proteins 70 (Hsp70) in a dose-dependent and time-dependent manner ( P , 0.01). Our in vivo antitumor effect results indicated that DCA markedly inhibited the growth of C6 glioma tumors in both C6 brain tumor-bearing rats and C6 tumor-bearing nude mice ( P , 0.01). DCA significantly induced the ROS production and decreased the mitochondrial membrane potential in tumor tissues. Our in vivo antitumor effect results also indicated that DCA has potential antiangiogenic effects. In conclusion, DCA may be a viable therapeutic agent in the treatment of gliomas.

[1]  S. Mukherjee,et al.  Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins. , 2012, Biochemical and biophysical research communications.

[2]  Guang-mei Zhang,et al.  Inhibition of Heat Shock Protein Response Enhances PS-341-Mediated Glioma Cell Death , 2012, Annals of Surgical Oncology.

[3]  I. Grivicich,et al.  Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr , 2011, Radiation oncology.

[4]  Xuan Zhang,et al.  Effects of dichloroacetate on the activation of the mitochondrial pathway in C6 cells in vitro , 2011 .

[5]  Qiang Zhang,et al.  The antiangiogenic efficacy of NGR-modified PEG–DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats , 2011, Journal of drug targeting.

[6]  Chee Wee Gan,et al.  Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. , 2010, Biomaterials.

[7]  Victor C Yang,et al.  Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. , 2010, Biomaterials.

[8]  Qiang Zhang,et al.  The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. , 2010, Biomaterials.

[9]  L. Galluzzi,et al.  Targeting mitochondria for cancer therapy , 2010, Nature Reviews Drug Discovery.

[10]  D. Jayne,et al.  Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells , 2010, British Journal of Cancer.

[11]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[12]  Qiang Zhang,et al.  Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo , 2010, AAPS PharmSciTech.

[13]  Erwin G. Van Meir,et al.  Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.

[14]  A. Lassman,et al.  Advances in the Treatment of Malignant Gliomas , 2010, Current oncology reports.

[15]  Divya Pathania,et al.  Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. , 2009, Advanced drug delivery reviews.

[16]  S. Rosen,et al.  Targeting the Warburg effect in hematological malignancies: from PET to therapy , 2009, Current opinion in oncology.

[17]  M. Andreeff,et al.  Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. , 2009, Cancer research.

[18]  L. Buie,et al.  Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme , 2008, The Annals of pharmacotherapy.

[19]  M.-H. Lee,et al.  Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.

[20]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[21]  Wengang Cao,et al.  Dichloroacetate (DCA) sensitizes both wild‐type and over expressing Bcl‐2 prostate cancer cells in vitro to radiation , 2008, The Prostate.

[22]  Volker W Stieber,et al.  Advances in radiation therapy for brain tumors. , 2007, Neurologic clinics.

[23]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[24]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[25]  T. Mak,et al.  Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? , 2007, Science's STKE.

[26]  Raoul Kopelman,et al.  Brain cancer diagnosis and therapy with nanoplatforms. , 2006, Advanced drug delivery reviews.

[27]  F. Zunino,et al.  Effect of a Novel Vacuolar-H+-ATPase Inhibitor on Cell and Tumor Response to Camptothecins , 2006, Journal of Pharmacology and Experimental Therapeutics.

[28]  M. Souweidane,et al.  Endoscopic resection of solid intraventricular brain tumors. , 2006, Journal of neurosurgery.

[29]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[30]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[31]  M. Momoi,et al.  Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS , 2004, Brain and Development.

[32]  Ha-won Jeong,et al.  Antitumor effect of the cinnamaldehyde derivative CB403 through the arrest of cell cycle progression in the G2/M phase. , 2003, Biochemical pharmacology.

[33]  G. Kroemer,et al.  Heat shock proteins: endogenous modulators of apoptotic cell death. , 2001, Biochemical and biophysical research communications.

[34]  W. Pardridge.  BBB-Genomics: creating new openings for brain-drug targeting. , 2001, Drug discovery today.

[35]  G. Heigenhauser,et al.  Effects of PDH activation by dichloroacetate in human skeletal muscle during exercise in hypoxia. , 2000, American journal of physiology. Endocrinology and metabolism.

[36]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[37]  J. Buolamwini.  Cell cycle molecular targets in novel anticancer drug discovery. , 2000, Current pharmaceutical design.

[38]  R. A. Howlett,et al.  Effects of dichloroacetate infusion on human skeletal muscle metabolism at the onset of exercise. , 1999, American Journal of Physiology. Endocrinology and Metabolism.

[39]  T. Batchelor,et al.  New treatment strategies for malignant gliomas. , 1999, The oncologist.

[40]  P. Stacpoole,et al.  Clinical pharmacology and toxicology of dichloroacetate. , 1998, Environmental health perspectives.

[41]  Y. Kuroda,et al.  Effects of Dichloroacetate on Pyruvate Metabolism in Rat Brain in Vivo , 1984, Pediatric Research.

[42]  G. Soltész,et al.  Dichloroacetate in the treatment of congenital lactic acidosis , 1984, Journal of Inherited Metabolic Disease.

[43]  N. Haugaard,et al.  Effects of Dichloroacetate on Brain Pyruvate Dehydrogenase , 1984, Journal of neurochemistry.

[44]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[45]  N. Munshi,et al.  Dichloroacetate Induces Apoptosis in Endometrial Cancer Cells , 2007 .

[46]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[47]  R. Bersin,et al.  A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. , 1992, The New England journal of medicine.

[48]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.